Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Microbix Biosystems Inc T.MBX

Alternate Symbol(s):  MBXBF

Microbix Biosystems Inc. develops and commercializes biological and technological solutions for human health and wellbeing. It enables the commercialization of diagnostic assays by making a range of critical ingredients and devices for the global diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment products (QAPs) that support clinical lab proficiency testing, enable assay development and validation, or help ensure the quality of clinical diagnostic workflows. Its segments include development, manufacturing and sales of products relating to the medical diagnostics industry, namely antigens as test ingredients, quality assessment products to help ensure the accuracy of test workflows and viral transport medium to enable collection of patient test samples and, and development and commercialization of novel and proprietary products or technologies, such as Kinlytic. Its Kinlytic urokinase is a biologic thrombolytic drug used to treat blood clots.


TSX:MBX - Post by User

Bullboard Posts
Comment by longondmxon Aug 27, 2014 12:53pm
196 Views
Post# 22882704

RE:RE:RE:Here are the beneficiaries of the financing

RE:RE:RE:Here are the beneficiaries of the financing

AS AT MARCH 2014

Name and Principal Occupation within the past 5 years, province/state and country of residence

Position with the Corporation

Director Since

No. of Voting Securities Owned, Controlled or Directed as at January 31, 2014 (1)

Peter M. Blecher

Medical Doctor – Department of Emergency Medicine,

Lakeridge Health Hospital

Ontario, Canada

Director

December 6, 2005

515,207

Mark A. Cochran

Managing Director, John Hopkins Medicine, JHHC – Solutions, Maryland, USA

Previously, Chief Business Officer, Microbix Biosystems Inc.

Director

October 1, 1990 to August 28, 2002 and since October 16, 2002

519,277

Vaughn C. Embro-Pantalony

President and Chief Executive Officer of the Company,

Previously President, StratPath Management Inc.

Ontario, Canada

President, Chief Executive Officer, and Director

February 6, 2007

398,185

William J. Gastle (4)

Chairman & former Chief Executive Officer of the Company

Ontario, Canada

Executive Chairman and Director

October 1, 1990

5,489,109 (2)

Andrew C. Pollock (3) (5)

Sr. Vice President

Maple Leaf Consumer Foods

Ontario, Canada

Director

March 14, 2006

275,000

Joseph D. Renner (4)(5)

Pharmaceutical Executive

New Jersey, U.S.A

Director

February 25, 2003

1,665,000

Martin Marino(3)(4)(5)

Pharmaceutical Executive,

Ontario, Canada

Previously, Global General Counsel, Merck Generics Group, Germany

Director

February 17, 2009

225,000

Cameron Groome(3)(5)

Pharmaceutical Executive,

Ontario, Canada

Previously, Executive Vice-President, Bioniche Life Sciences Inc.

Director

March 16, 2012

200,000

Bullboard Posts